TriSalus Life Sciences, Inc. (TLSI)

TriSalus Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-24.92	-30.05	-59.36	-47.19	4.77
Depreciation & Amortization	0.69	0.74	0.68	0.4	-
Stock-Based Compensation	8.63	5.44	1.4	0.37	-
Other Adjustments	5.7	-7.43	6.16	11.81	-7.81
Change in Receivables	-0.4	-1.72	-1.98	-0.2	-
Changes in Inventories	0.72	-1.5	-1.07	-0.18	-
Changes in Accounts Payable	1.63	-4.38	2.84	5.25	0.95
Changes in Other Operating Activities	0.79	-1.94	0.75	-2.57	0.35
Operating Cash Flow	-21.24	-40.84	-50.58	-32.31	-1.74
Capital Expenditures	-0.93	-0.35	-0.59	-0.66	-
Sale of Property, Plant & Equipment	0.1	-	-	-	-
Purchases of Intangible Assets	-	-	-1	-1.13	-
Other Investing Activities	-	-	-	-	0.06
Investing Cash Flow	-0.85	-0.35	-1.59	-1.79	0.06
Long-Term Debt Issued	15	25	-	-	-
Net Long-Term Debt Issued (Repaid)	15	25	-	-	-
Issuance of Common Stock	25.65	15.61	37.03	0.09	-
Repurchase of Common Stock	-	-	-0.02	-	-
Net Common Stock Issued (Repurchased)	25.65	15.61	37.01	0.09	-
Issuance of Preferred Stock	-	-	18.82	13.5	-
Net Preferred Stock Issued (Repurchased)	-	-	18.82	13.5	-
Other Financing Activities	-1.65	-2.68	-1.2	-0.13	0.54
Financing Cash Flow	33.48	37.94	54.63	13.46	0.54
Net Cash Flow	11.4	-3.25	2.46	-20.64	-1.13
Free Cash Flow	-22.16	-41.19	-51.17	-32.97	-1.74
FCF Margin	-55.12%	-139.95%	-276.41%	-265.91%	-
Free Cash Flow Per Share	-0.67	-1.63	-5.45	-106.48	-7.93
Levered Free Cash Flow	-54.35	-15.66	-60.99	-47.77	6.07
Unlevered Free Cash Flow	-28.34	-43.59	-51.85	-34.19	-1.74

Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q